Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
Solange Peters(University Hospital of Lausanne), Tony Mok(Chinese University of Hong Kong), M. Pérol(Centre Léon Bérard), Rafael Rosell(Hospital Universitario Dexeus), Rafał Dziadziuszko(Gdańsk Medical University), Johannes Noé(Roche (Switzerland)), Alice T. Shaw(Dana-Farber Cancer Institute), Jin Seok Ahn(Chungnam National University), D. Ross Camidge(University of Colorado Denver), Ali Zeaiter(Roche (Switzerland)), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Dong‐Wan Kim(Seoul National University Hospital), Emmanuel Mitry(Roche (Switzerland)), Sophie Golding(Roche (Switzerland)), Peter N. Morcos(Roche (United States)), Bogdana Balas(Roche (Switzerland)), Shirish M. Gadgeel(Chinese University of Hong Kong)
Cited by 2,449
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k